載入中
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
前收盤價
US$5.03
−US$0.12 · -2.33%
盤前
US$5.03
US$0.00 · 0.00%
10月13日 上午9:19 ET
盤中時間採用ET。市場資料可能有所延遲。
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
日內區間
目前US$5.03
52週區間
目前US$5.03
盤中時間採用ET。市場資料可能有所延遲。
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
日內區間
目前US$5.03
52週區間
目前US$5.03
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | — | 3.51億 USD |
| 銷貨成本 | — | 8336.7萬 USD | 7009萬 USD | 6239萬 USD | 1.67億 USD |
| 毛利 | — | −8336.7萬 USD | −7009萬 USD | −6239萬 USD | 1.84億 USD |
| 研究與開發 | 1.48億 USD | 1.45億 USD | 1.33億 USD | 8883.6萬 USD | 1.67億 USD |
| 銷售、一般及管理費用 | 3286.3萬 USD | 4884.9萬 USD | 4991.9萬 USD | 4871.4萬 USD | 4578.5萬 USD |
| 營業費用 | 1.81億 USD | 1.1億 USD | 9407.2萬 USD | 6826萬 USD | 4578.5萬 USD |
| 利息收入 | 1637.6萬 USD | 2549萬 USD | 2922.4萬 USD | 1115.1萬 USD | 21.3萬 USD |
| 利息支出 | — | — | — | 1115.1萬 USD | — |
| 折舊和攤銷 | 41.6萬 USD | 41.6萬 USD | 41.6萬 USD | 26萬 USD | 2.9萬 USD |
| 營業利益 | −1.81億 USD | −1.93億 USD | −1.64億 USD | −1.31億 USD | 1.38億 USD |
| 淨利 | −1.58億 USD | −1.68億 USD | −1.36億 USD | −1.16億 USD | 1.21億 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.00
上漲空間 39.17%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1087.26萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM958.06萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF457.86萬0.00%954億 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS316.16萬0.01%338.04億 USD0.31%US$78.17-0.23%
iShares Biotechnology ETFIBB258.7萬0.02%108.2億 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO217.94萬0.01%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA187.27萬0.01%217.13億 USD0.03%US$32.66-0.40%
U.S. Micro Cap Portfolio ETFDFMC120.93萬0.02%75.44億 USD0.43%US$57.70-0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAU.S. Micro Cap Portfolio ETFDFMCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
